Filing search / Kineta, Inc. / "Targets"

Search information

Kineta, Inc.

Companies

"Targets"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

72 results

Newest first Best match first

antibody drugs directed against novel innate immune targets. Kineta’s focus on innate immunity differentiates it from other immuno-oncology companies … , NK and T cell responses can reverse immunosuppression and drive anti-tumor activity. While many immuno-oncology targets address either T cell

21 Mar 24

4:06pm

Agreement In connection with the Company’s research into innovative immuno-oncology drug targets, the Company acquired rights to a group of fully human … License Agreement In connection with the Company’s research into innovative immuno-oncology drug targets, the Company acquired rights to a group

3 Nov 23

4:04pm

License Agreement In connection with the Company’s research into innovative immuno-oncology drug targets, the Company acquired rights to a group of fully … Program License Agreement In connection with the Company’s research into innovative immuno-oncology drug targets, the Company acquired rights to a group

11 Aug 23

4:07pm

into innovative immuno-oncology drug targets, the Company acquired rights to a group of fully human antibodies from Gigagen, Inc., a wholly owned subsidiary … immuno-oncology drug targets, the Company acquired rights to a group of fully human antibodies from Gigagen directed to CD27. Pursuant to a material

11 May 23

5:22pm

immune pathways and has built the Innate Immunity Development Platform that is designed to develop fully human antibody drugs to exploit these targets … represents the three major mechanisms of cancer immune resistance to therapies and the targets that Kineta is exploiting to develop novel anticancer therapies

31 Mar 23

4:05pm

Kineta Completes Reverse Merger with Yumanity Therapeutics

Kineta Completes Reverse Merger with Yumanity Therapeutics

Kineta Completes Reverse Merger with Yumanity Therapeutics

Business combination disclosure

14 Nov 22

8:44am

Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Prospectus supplement

4:21pm

S-4/A

0tae4m8xgse0hhp

Registration of securities issued in business combination transactions (amended)

4 Nov 22

4:49pm

S-4/A

tcvwc

Registration of securities issued in business combination transactions (amended)

24 Oct 22

9:14am

S-4/A

EX-10.45

7lx esnr6871s

Registration of securities issued in business combination transactions (amended)

24 Oct 22

9:14am

S-4/A

EX-10.45

x9r8l4olpqwc9h 777c6

Registration of securities issued in business combination transactions (amended)

3 Oct 22

4:54pm

S-4/A

uhqvhdbovgs

Registration of securities issued in business combination transactions (amended)

3 Oct 22

4:54pm

S-4

vz8wgizaoq1j0e

Registration of securities issued in business combination transactions

29 Aug 22

12:00am

Filing search / Kineta, Inc. / "Targets"

72 results

Top filers

Top filing types

Recent filing years